CTSO beat EPS expectations by 19.60%
Aug 13, 2024, 11:31 PM
0.00%
What does CTSO do
CytoSorbents Corp., based in Princeton, New Jersey, specializes in critical care immunotherapy and blood purification technology, having launched its IPO in 2005. The company's flagship product, CytoSorb, aims to mitigate cytokine storms in severe medical conditions, alongside other products and candidates like VetResQ and DrugSorb-ATR.
Cytosorbents (CTSO) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Cytosorbents's actual EPS was -$0.08, beating the estimate of -$0.10 per share, resulting in a 19.60% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.